Another explanation for the potential disruption of ErbB4 tumor suppressor activity by the V673I, LL783/4AA, and L985A mutations is that these mutations may abrogate ErbB4 expression and/or tyrosine phosphorylation. Here, ERBB4 is linked to neoplasm.